Loss of imprinting in colorectal cancer

Loss of imprinting (LOI) has been implicated in the predisposition to certain colorectal cancers. Insulin-like growth factor II (IGF2) is an imprinted gene in which the maternal allele is normally silenced. In the January 16 Proceedings of the National Academy of Science, Nakagawa et al. describe the development of a fluorescence-based primer extension assay (SnuPE) to examine whether LOI is associated with allele-specific methylation in colorectal cancer samples (Proc Natl Acad Sci USA 2001,

By | January 18, 2001

Loss of imprinting (LOI) has been implicated in the predisposition to certain colorectal cancers. Insulin-like growth factor II (IGF2) is an imprinted gene in which the maternal allele is normally silenced. In the January 16 Proceedings of the National Academy of Science, Nakagawa et al. describe the development of a fluorescence-based primer extension assay (SnuPE) to examine whether LOI is associated with allele-specific methylation in colorectal cancer samples (Proc Natl Acad Sci USA 2001, 98:591-596). They demonstrate that LOI is not a consequence of microsatellite instability or a deficiency in the process of mismatch repair. A link is established between LOI and methylation of both alleles of IGF2 at CpG sites, which are important for binding of the CTCF protein. The authors also observed LOI in matched normal tissues in some patients, suggesting that LOI events may precede tumour formation. These results establish a role for methylation and chromatin in colon cancer epigenetics.

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham